ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)
Association between preoperative serum MMP-9 and histopathological features of thyroid tumors
Ruxandra Dobrescu 1 , Catalina Picu 1 , Sorina Schipor 1 , Adriana Padure 1 , Liliana Parvu 1 , Dana Manda 1 , Dumitru Ioachim 1 , Corin Badiu 1, & Andra Caragheorgheopol 1
1‘CI Parhon’ National Institute of Endocrinology, Bucharest, Romania; 2‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania.
Introduction: Matrix metalloproteinase-9 (MMP-9) is a zinc dependent proteolytic enzyme used by cells for degradation of the extracellular matrix during invasion and migration. There are only a few reports regarding the role played by MMP-9 in papillary thyroid carcinoma (PTC).
Aim: To evaluate the association between MMP-9 secretion, reflected by preoperative serum levels and the histopathological features of thyroid tumors.
Materials and methods: We assessed serum MMP-9 in 329 subjects: 309 patients with thyroid tumors and 20 healthy controls (C). Patients were divided into 2 groups, following the pathology report: benign disease group (BD) (n=176, aged 50.5±12.88 years) and PTC group (n=133, aged 48.6±14.92 years). In the PTC group histopathological features of thyroid tumors were analyzed according to pathological stage, histological subtype, multifocality and invasion. The histology showed classic PTC (cPTC) in 49 patients, follicular variant (fvPTC) in 52 and aggressive forms (AGR) in 32 patients. Sera were collected before patients underwent surgery. MMP-9 was measured by Quantikine Elisa kit (R&D System). The study was approved by Ethics Committee of the Institute.
Results: We found a significant difference in serum MMP-9 levels between controls and thyroid tumors (BD+PTC) (mean±S.E.M.: 561.45±49.37 ng/ml vs 787.47±31.24 ng/ml, P<0.0001). According to the pathology tumor stage (T1–T4), we found higher MMP-9 levels in T3 (869±79.48 ng/ml) compared to more incipient stages (T1 vs T3 P<0.01, T2 vs T3 P<0.03 respectively). fvPTC showed lower MMP-9 levels vs cPTC or AGR (596.38±34.76 ng/ml vs 760.35±70.54 ng/ml or vs 835.75±109.9 ng/ml, respectively, P<0,05). There was no significance between cPTC and AGR. There was no difference in MMP-9 in terms of multifocality, but patients with invasive tumors had significantly higher serum MMP-9 than non-invasive ones (838.14±80.3 ng/ml vs 618.68±30.9 ng/ml, P<0.02).
Conclusions: Preoperative serum MMP-9 might differentiate patients at risk for invasive and more aggressive tumor behavior, with implications in post-surgical radioiodine treatment and follow-up.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more